Takeda Oncology
Umut Ata Turkdogan, PharmD, is an experienced professional in the field of oncology medical information. Currently serving as Associate Director of Global Oncology Medical Information & Review at Takeda Oncology since January 2024, Umut has previously held key positions at EMD Serono, Inc. as Manager of Medical Information & Review, and at Merck as an Oncology Global Medical Information Scientist. Prior experience includes roles at Ashfield, Penn Medicine, and various rotations in emergency medicine and ambulatory care, where Umut developed innovative pharmacy services and led quality improvement initiatives. As a research assistant at Thomas Jefferson University, significant contributions were made towards cancer research and drug design. Umut holds a Doctor of Pharmacy degree from Thomas Jefferson University and a Bachelor's degree in Biochemistry from Rutgers University.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.